ASCO Annual Meeting Coverage
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
ASCO Review: Progress Is Where You Find It
In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine.
With New Leadership, Roche Goes Back To Basics At ASCO
In a time of internal transition, Roche emphasized its deep roots and broad pipeline at its annual event alongside the American Society for Clinical Oncology meeting.
Latest From ASCO
Kura May Have Found A Place For Tipifarnib In Head-And-Neck Cancer
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.
Merck's Keytruda Doubled PFS In Some Colorectal Cancer Patients In ASCO Late-Breaker
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals
Data from CheckMate-9LA and -227 that will be presented at the ASCO virtual meeting support a low-dose chemo combo with the two drugs and the newly US FDA-approved chemo-free indication.
Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy
Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.
Late-Breakers To Look Out For At ASCO 2020
ASCO 2020, which takes place from 29-31 May, will necessarily depart from its predecessors in location, content and delivery. Here, with input from Biomedtracker and Datamonitor Healthcare, we take a look at what can be expected during this year’s late-breaking clinical trial sessions.
ASCO 2020: BCMA CAR-T Race Heats Up Between Bristol And Janssen
The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.
Weak SOPHIA OS Signal Dampens Enthusiasm For MacroGenics’ Margetuximab
Whether MacroGenics’ margetuximab can produce an overall survival benefit from the SOPHIA study could be key to its commercial fortunes, say analysts. The company remains optimistic.
Roche Outlines Use Of Real-World Evidence In Entrectinib NDA
Roche used its Flatiron Health oncology EHR database to generate an external control arm for pivotal single-arm data supporting the personalized medicine candidate, which has an 18 August user fee goal.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.